E-ISSN 2149-2530
Original Article
The evaluation of serum biomarkers in patients with sarcoidosis: Can visfatin be a new biomarker for sarcoidosis?
1 Department of Pulmonology, Yedikule Pulmonary Diseases and Thoracic Surgery Education and Research Hospital, Istanbul, Turkey  
2 Department of Pulmonology, Koc University, Faculty of Medicine, Karabuk, Turkey  
3 Department of Pulmonology, Karabuk University, Faculty of Medicine, Istanbul, Turkey  
4 Department of Biochemical, Bagcılar Education and Research Hospital, Istanbul, Turkey  
Turk Thorac J ; 5: -
DOI: 10.5152/TurkThoracJ.2019.180112
Key Words: sarcoidosis; biomarkers; visfatin; inflammation

Objective: Sarcoidosis is a chronic systemic inflammatory disease which can affect multiple organ systems. The role of biomarkers in the diagnosis and prognosis of sarcoidosis is increasing. Interest in the role of adipose tissue mediated inflammation in the pathogenesis of the inflammatory diseases has increased in recent years. Visfatin is a proinflammatory adipocytokine which has been studied for several inflammatory diseases such as diabetes mellitus, obesity and metabolic syndrome. Our aim is to assess serum visfatin levels in sarcoidosis and its relation with other markers of inflammation (CRP, ACE and ESR).


Material and Methods: We enrolled 59 patients with sarcoidosis and 21 healthy controls. We measured plasma levels of visfatin along with serum CRP, ESR, ACE using ELISA (enzyme-linked immunosorbent assay) kits (Blue Gene Biotech, Shanghai, China).


Results: Visfatin levels were not significantly different between patients and control subjects (29.9±15.8 ng/ml for patients and 23.93±16.73 ng/ml for controls, p=0.15) and there was no correlation between visfatin and serum CRP, ACE or ESR in patients with sarcoidosis.


Conclusion: Visfatin recently is being discussed as biomarker for inflammatory diseases in several studies and results are controversial. In our study, no differences were found in serum level of visfatin between patients with sarcoidosis and control group.


Cite this article as: Tanrıverdi E, İliaz S, Cortuk M, et al. The evaluation of serum biomarkers in patients with sarcoidosis: Can visfatin be a new biomarker for sarcoidosis? Turk Thorac J 2019; DOI: 10.5152/TurkThoracJ.2019.180112

Key Words
Author's Corner
AVES | Copyright © 2019 Turkish Thoracic Society Latest Update: 20.06.2019